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40-word-or-less summary of article's main point 
Mycoplasma pneumoniae (Mp) is carried in the upper respiratory tract (URT) of mice after 
symptomatic infection. B cells and Mp-specific antibodies are crucial for Mp clearance in the 
lungs of mice, but are limited in clearing Mp from the URT. 
 
Abstract 
Carriage of Mycoplasma pneumoniae (Mp) in the nasopharynx is considered a prerequisite 
for pulmonary infection. Interestingly, Mp carriage is also detected after infection. While B 
cells are known to be involved in pulmonary Mp clearance, their role in Mp carriage is 
unknown. We here show in a mouse model that Mp persists in the nose after pulmonary 
infection, similar to humans. Infection of mice enhanced Mp-specific immunoglobulin (Ig) M 
and IgG levels in serum and bronchoalveolar lavage fluid. However, nasal washes only 
contained elevated Mp-specific IgA. These differences in Ig compartmentalization correlated 
with differences in Mp-specific B cell responses between nose- and lung-draining lymphoid 
tissues. Moreover, transferred Mp-specific serum Igs had no effect on nasal carriage in B 
cell-deficient μMT mice, while this enabled μMT mice to clear pulmonary Mp infection. This is 
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the first evidence that humoral immunity is limited in clearing Mp from the upper respiratory 
tract. 
 
Keywords 
Mycoplasma pneumoniae; pneumonia; B cells; antibodies; carriage; mouse model; 
immunization; vaccine 
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Introduction 
Mycoplasma pneumoniae (Mp) is a frequent cause of childhood community-acquired 
pneumonia (CAP) worldwide [1], and currently is the most commonly detected bacterial 
cause of CAP in hospitalized children in the U.S. [2]. We and others observed that besides 
causing upper and lower respiratory tract (URT and LRT) infection, Mp is also carried in the 
URT of asymptomatic children [3-7]. Carriage is considered a prerequisite for infection [3, 8-
10]. Interestingly, carriage also occurs following symptomatic infection [11]. Several studies 
in humans demonstrated the presence of Mp in the nasopharynx up to eight months after 
respiratory tract infection [3-7]. 
 B cells are of crucial importance for the host defense against multiple pathogens, as 
B cell activation can result in the production of specific immunoglobulins (Igs) that neutralize 
the pathogen [12]. Following an initial Mp respiratory tract infection Mp-specific IgM is 
detectable in serum within one week, and increased amounts of Mp-specific IgG can be 
found from two weeks post infection (p.i.) [13, 14]. Mp-specific IgA is produced early after 
infection and its levels both peak and decrease earlier than IgM or IgG [15]. Indeed, B cells 
are known to be involved in pulmonary Mp clearance [16-20]. Furthermore, patients with 
hypogammaglobulinemia are at greater risk for Mp pulmonary disease and/or 
extrapulmonary manifestations [21-25]. It is likely that carriage of Mp by these patients make 
them susceptible to the development of symptomatic Mp infection. 
 In contrast to the known important role of B cells in clearance of a pulmonary 
infection, limited knowledge exists on the role of B cells in the control of Mp carriage in the 
URT. We therefore set out to determine whether humoral immunity contributes to clearance 
of Mp carriage from the URT. Since this is difficult to study in human subjects, we further 
developed a C57BL/6 mouse model to study Mp (strain M129) infections and the role of 
humoral immunity on control of these infections. 
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Methods 
Mice 
C57BL/6 mice were purchased from Charles River Laboratories and used at 8–12 weeks of 
age. µMT transgenic mice (C57BL/6×FVB×129) [26] were bred and housed in the animal 
facilities of the Erasmus MC under specific pathogen-free conditions. All experiments were 
approved by the Animal Experiments Committee of the Erasmus MC, Rotterdam, The 
Netherlands. 
 
Bacteria 
Mp reference strain M129 (subtype 1, ATCC 29342) was cultured at 37°C/5% CO2 in SP4 
medium (pH 7.8–8.0) for 72 hours and concentrated in fresh SP4 medium to 1×109–10 colony-
forming units (CFU)/ml (Supplementary Data). To track Mp, bacteria were labeled with 10 μM 
carboxyfluorescein diacetate succinimidyl ester (CFSE) according to the manufacturer's 
instructions (Molecular Probes). 
 
Mp infection and carriage mouse model 
Mice were inoculated intranasally with 1×109 CFU of M129 diluted in 50 µl SP4 medium. 
Control mice were inoculated with 50 µl SP4 medium. On indicated days after Mp 
inoculation, body weight was measured and mice were sacrificed. Lung washes and nasal 
fluid samples (washes and brushes) were collected. Cells from lungs, lymph nodes, and 
nasal passages (mucosa and nasal-associated lymphoid tissue [NALT] [27]) were isolated. 
Detailed methods for sample procedures are included in Supplementary Data. 
Serum transfer 
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Sera were collected and pooled from wild-type (WT) and µMT mice on day 14 p.i., diluted 
with PBS (1:1.3), and 200 μl was injected intravenously into each WT and µMT recipient 
mice at day 15, 16, and 22 p.i. One week after the last serum transfer, recipient mice were 
sacrificed. Sera were devoid of Mp as confirmed by a negative PCR for Mp [28]. 
 
Mp quantification 
The presence of Mp was detected either by PCR [28] or culture of bronchoalveolar lavage 
fluids (BALF) and nasal fluid samples (100 µl undiluted and 10-fold diluted) on SP4 agar 
plates at 37°C. Suspensions of spleen, liver, and immersed cotton swabs of articular 
surfaces were processed in a similar fashion. 
 
Mp phagocytosis and killing 
Mp M129 was incubated with sera from infected WT mice. As control, sera from uninfected 
mice were used. Murine RAW 264.7 macrophages were incubated with the respective 
bacteria for 20 min, washed, and at time point 0 and 180 min, cells were lysed to determine 
bacterial load (CFU/105 RAW cells) by culture on SP4 agar plates. 
 
Histopathology scoring 
Histopathology scoring (HPS) of lung sections was performed without knowledge of the 
treatment or time after infection of mice. The modified HPS system [29] assigns values from 
0 to 10 by grading immune cell infiltrates in alveoli and bronchi for distribution, severity of 
inflammation, presence of necrosis, and presence of perivascular, peribronchial, and 
peribronchiolar cuffing (Supplementary Data). 
Quantification of antibodies 
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Total antibody concentrations (µg/ml) and Mp-specific antibodies (arbitrary units [AU]/ml) 
were quantified by ELISA as described in Supplementary Data. 
 
IgA ASC ELISpot 
The frequency of Mp-specific and total IgA-producing antibody secreting cells (ASCs) in 
MLN, CLN, and nasal passages was measured by enzyme-linked immunospot (ELISpot) 
assay using a commercially available kit (Mabtech) as described in Supplementary Data. 
 
Flow cytometry 
Aliquots of single-cell suspensions were incubated with appropriate dilutions of antibodies for 
30 min on ice. Cells were subsequently analyzed using a FACS Canto II (BD Biosciences) 
and FlowJo 10 software (Tree Star). Monoclonal antibodies and the gating strategy are 
described in Supplementary Figure S1. 
 
Cytokine analysis 
Cytokines were measured in BALF and nasal lavage fluid by a multiplex fluorescent-bead-
based immunoassay (Procarta multiplex, eBioscience). 
 
Statistical analysis 
R software environment (version 3.4.0) and GraphPad Prism (version 5.01) were used for 
statistical analysis. The Welch’s t-test, Mann-Whitney U test, Kruskal-Wallis test with post 
hoc Dunn’s multiple comparisons test of selected pairs, Fisher exact test or 2 test were used 
to determine statistical significance. Family-wise error rates were controlled using the Holm-
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Bonferroni Method. Association between paired samples was tested using the Pearson's 
product moment correlation coefficient. Statistical significance was defined as p<0.05. 
 
Results 
Mp persists in the nose after pulmonary infection 
To unravel the role of B cells in Mp pulmonary infection and nasal carriage, we further 
developed a mouse model for Mp infection using the Mp reference strain M129 (subtype 1) in 
C57BL/6 mice [30-32]. Intranasal inoculation of anaesthetized C57BL/6 mice with 1×109 CFU 
of Mp M129 resulted in a mean relative body weight loss of 4% within three days (Figure 1A). 
After two weeks, infected mice returned to their initial weight and from then on were 
comparable to control mice, which did not lose weight at any time point. BALF cultures of 
infected mice, but not control mice, were positive for Mp with the highest median bacterial 
load of 3×104 CFU/ml on day three p.i. (Figure 1B). Bacterial loads in BALF gradually 
declined within two weeks, and were undetectable at four weeks after infection. In contrast to 
the lung, Mp persisted in the nose. During the first two weeks of infection, median bacterial 
loads were 5–9×104 CFU/ml, and at day 42 p.i., Mp was still detected in the nasal lavage 
fluid of 5 out of 6 mice, with a median bacterial load of 6×102 CFU/ml (Figure 1C). The only 
mouse in which Mp was not detected in the nasal lavage fluid at day 42 p.i. did show a 
positive culture for Mp when nasal brush samples were analyzed (data not shown). 
 These findings were corroborated using CFSE-labeled Mp M129: CFSE-labeled 
bacteria were detected on the bronchial epithelium and in alveoli forming islets in the lungs at 
day one p.i. (Figure 1D). The loss of fluorescence from the lungs of infected mice at day 
three p.i. likely resulted from bacterial replication, as high bacterial loads were detected in the 
lungs at this same time point (Figure 1B) and CFSE signals are reduced two-fold at each 
bacterial division [33]. This was confirmed when sections were incubated with an anti-Mp 
antibody: Mp was detected in the lungs both at day one and day three p.i. (data not shown). 
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By contrast, CFSE-labeled Mp was detected on the nasal respiratory epithelium at both time 
points analyzed, without an apparent loss of fluorescence intensity between these time 
points (Figure 1E). In contrast to previous studies showing invasion and intracellular survival 
of Mp in vitro [34, 35], we did not observe CFSE-labeled Mp within respiratory epithelial cells 
(Supplementary Figure S2). 
 
Specific IgG antibodies in serum and BALF coincide with clearance of Mp from the 
lungs 
To define the course of pneumonia following infection with Mp and identify immune 
mechanisms that contribute to pulmonary clearance, we examined pulmonary inflammation 
by HPS as well as immune cells and antibodies in BALF at the indicated time points after 
inoculation of mice with Mp. Pulmonary inflammation, demonstrated by both inflammatory 
infiltrates and necrosis in HPS (Figure 2A) and increased BALF leukocytes (Supplementary 
Figure S3A), was most severe on day three p.i., and resolved at day 28 p.i. At day three p.i., 
the infected lungs showed pulmonary consolidation at gross pathology and histopathology 
showed thickened alveolar septa characterized by infiltration of inflammatory infiltrates and 
presence of perivascular and peribronchiolar cuffing (Figure 2B). Using flow cytometry, we 
detected a major influx of granulocytes, monocytes, and dendritic cells (DCs) into BALF at 
day three p.i. (Supplementary Figure S3B), which corroborated the inflammation seen 
histologically at that time point (Figure 2). Additionally, increased numbers of CD4+ and CD8+ 
T cells, NK cells, and B cells were detected in infected lungs, albeit at much lower 
frequencies than observed for the innate immune cells (Supplementary Figure S3C). 
 Since B cells only marginally infiltrated the lungs, we evaluated the systemic and local 
humoral immune response against Mp. Both Mp-specific IgM and IgG were detected in 
serum from day seven p.i. (Figure 3A). While specific IgM levels declined after day 28 p.i., 
specific IgG persisted at high levels. Further analysis revealed that both IgG1 and IgG2a 
subclasses were present in the Mp-specific IgG pool (Figure 3B), which indicates neutralizing 
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and complement-dependent killing of Mp. Indeed, we found that the serum of Mp-infected 
WT mice had the capacity to opsonize Mp resulting in enhanced internalization and killing of 
the bacteria by macrophages in vitro (Figure 3C). 
 Notably, Mp-specific IgG levels in the nasal lavage fluid were far below those 
detected in BALF on day 42 (Figure 4A). The opposite was seen for specific IgA: the levels 
were highly increased in nasal lavage fluid but not in BALF. Total IgG and IgA levels were 
similar in BALF and nasal lavage fluid (Supplementary Figure S4). ELISpot analysis revealed 
that Mp-specific IgA ASCs were present in CLN and nasal passages seven days p.i., with 
highest numbers in CLN (Figure 4B). In contrast and in line with the data obtained by ELISA, 
Mp-specific IgA ASCs were not present in MLN. 
 This prompted us to investigate the activation and expansion of B cells in the cervical 
and mediastinal lymph nodes (CLN and MLN) that drain the URT and LRT, respectively. B 
cell expansion and activation was observed in both MLNs and CLNs, but not in peripheral 
(inguinal) lymph nodes (PLNs), which indicates that Mp infection induced a B cell response 
only locally and not systemically (Figure 4C and 4D). Interestingly, the expression levels of 
CD86 were higher on B cells in MLN than on those in CLN (Figure 4E). Notably, increased 
numbers of CD86+ B cells were still found in CLN, but not in MLN, on day 28 p.i., albeit not 
significant from controls. Together, these findings demonstrate a distinct difference in the B 
cell response to Mp between LRT and URT lymphoid tissues. 
 
B cells are essential for pulmonary clearance of Mp and affect Mp carriage 
To further evaluate the contribution of B cells to protective immunity against Mp, we 
assessed whether bacterial replication in the URT and LRT is altered in μMT mice. Similar to 
WT mice, an initial body weight loss at day three p.i. was measured in μMT mice. Yet, while 
infected WT mice were back at their initial weight within two weeks and from then on 
continued to gain weight, the weight of μMT mice remained lower than that of WT mice at all 
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time points analyzed (Figure 5A). Interestingly, while Mp was no longer detectable in BALF of 
WT mice at day 28 p.i., bacteria were still detectable at day 42 in μMT mice, albeit at 
relatively low levels (Figure 5B). In the absence of antibodies mycoplasma is suggested to be 
more prone to disseminate extrapulmonary [16-18], however, spleen, liver, and articular 
surfaces of μMT and WT mice on day 14 and 28 p.i. were negative for Mp by culture and 
PCR (data not shown). 
 In line with the long-term presence of Mp in the lungs of μMT mice, both the HPS of 
alveoli (Figure 5D) and the lung leukocyte number (Figure 5E) of μMT mice was higher than 
those of WT mice on day three p.i. Moreover, in comparison with WT mice, the lungs of μMT 
mice showed even increased numbers of leukocytes on day 42 p.i. (Figure 5E and 5F). 
 Interestingly, also significantly reduced control of bacterial replication was noted in the 
URT of μMT mice (Figure 5C). Mp was detected in nasal lavage fluid of all µMT mice and the 
median bacterial loads remained at similar levels from day 14 to 42 p.i. (2×104 CFU/ml), 
while median bacterial loads in WT mice decreased from 4×104 to 6×102 CFU/ml during this 
time period. In the absence of B cells, significantly higher levels of the proinflammatory 
mediators interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1 were detected in 
nasal lavage fluid of μMT mice at day 3 p.i. (Figure 5G). 
 
Serum transfer from WT infected mice to infected μMT mice only controls bacterial 
replication in the lungs 
To specifically examine the contribution of the IgG and IgM antibodies in serum to clearance 
of bacteria from the nose, we passively immunized μMT mice with serum from infected WT 
mice. Therefore, donor and recipient mice were both intranasally inoculated with 1×109 CFU 
of Mp M129. Two weeks later, when recipient WT and μMT mice still had similar median 
levels of bacterial loads in the lungs (Figure 5B), donor serum was transferred (Figure 6A). 
As shown in Figure 6B, μMT mice were only able to control Mp replication in the lungs upon 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 12 
transfer of serum from infected WT mice, as indicated by the similar bacterial load in the 
lungs of μMT and WT mice at day 28 p.i. Transfer of μMT serum, however, did not reduce 
Mp loads in the lungs of infected μMT recipient mice; pulmonary Mp loads in these μMT 
recipients were similar to those of untreated controls at day 28 p.i. (Figure 6B). Moreover, 
these findings were corroborated by the detection of Mp-specific IgG in the BALF of four out 
of six μMT recipient mice two weeks after WT serum transfer (Figure 6D). Mp persisted in the 
lungs of the two μMT recipient mice, whose BALF did not contain Mp-specific IgG after 
serum transfer (Figure 6E). 
 By contrast, the bacterial loads in the nose were comparable for all recipient μMT 
mice (with a median of 2×104 CFU/ml), irrespective of the specific source of the serum 
(Figure 6C). The median concentration of Mp-specific and total IgG in nasal lavage fluid of 
infected μMT mice after serum transfer was 5 AU/ml and 0.005 μg/ml, respectively, at day 28 
p.i. Notably, there was no significant difference between Mp-specific IgG levels in BALF and 
nasal lavage fluid of μMT mice receiving WT serum (median 6 vs. 5 AU/ml). In addition to 
nasal lavage fluid and BALF, Mp-specific and total IgG antibodies were also detected in 
serum of μMT mice after WT serum transfer (Supplementary Figure S5). 
 
Discussion 
Here, we show Mp persistence after infection in a further developed mouse model for Mp 
infection [30-32]. B cells in lung-draining MLNs become activated and expand early after Mp 
infection, resulting in elevated levels of Mp-specific IgM and IgG antibodies in serum and 
BALF. This B cell activation in MLNs may be key to clear the infection as shown by our 
observations in μMT mice, in which Mp infection leads to chronic pulmonary disease, 
characterized by failure to thrive, more severe pneumonia, and long-lasting innate and 
adaptive compensatory immune cell infiltrates, due to bacterial persistence in the lungs. 
Conversely, μMT mice do clear Mp infections in the lungs when passively immunized with 
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serum from infected WT mice. Additionally, we showed that the induced antibodies enhance 
phagocytosis and killing by macrophages in vitro, which suggests that they can contribute to 
resolve Mp infections in vivo. 
 In contrast to the lungs, B cells in the nose-draining CLN did not become activated by 
the presence of Mp. As the draining lymph nodes are the major sites of B cell induction 
following respiratory tract infection [36], the observed differences in B cell expansion and 
activation between the nose-draining CLN and lung-draining MLN suggest a different control 
of bacterial replication in the URT compared to that in the LRT. Indeed, Mp persisted in the 
nose of WT mice while the bacterium was cleared from the lungs during the course of 
infection. Importantly, these data mimic the findings in humans, where Mp is carried in the 
URT of children up to eight months after symptomatic infection [3-7]. The observed 
difference in B cell responses between LRT and URT lymphoid tissues is in line with the low 
levels of Mp-specific IgG and IgM in the nasal lavage fluid. It is unlikely that Mp-specific IgG 
does not reach the URT, as total IgG levels were similar in nasal lavage fluid and BALF, and 
we observed comparable bacterial loads in the URT of WT mice as in that of Bruton tyrosine 
kinase (Btk)-deficient mice, which have reduced peripheral B cell numbers (data not shown). 
In contrast to Mp-specific IgG, Mp-specific IgA was more abundant in nasal lavage fluid than 
in BALF of Mp-infected mice. While this has not been shown before for bacterial infections, 
similar observations were made in influenza virus-infected mice [37]. The vast majority of 
ASCs in the URT (NALT) of such mice were found to produce IgA, whereas B cell responses 
in the LRT (lungs) mainly generated IgG and IgM [38]. In fact, we also detected Mp-specific 
IgA ASCs in CLN and nasal passage, but not in MLN, which is in line with observations from 
Hodge and Simecka [39], showing mycoplasma-specific IgA ASCs in nasal passages but not 
in the lungs from mice following nasal immunization. Furthermore, these data also 
corroborate our findings on the presence of IgA in nasal washes but not in BALF. Detection 
of Mp-specific IgA-producing ASCs in the nasal passage, albeit at lower numbers than in 
CLN, may indicate that some of the activated B cells have migrated into the nasal passage. 
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 The locally induced immune responses upon Mp carriage in the URT and infection of 
the LRT are distinct. We show that Mp-specific IgG controls Mp in the lungs and does not 
impact on carriage in the URT. By contrast, Mp-specific IgA and IgA ASCs in the URT affect 
Mp carriage, but do not mediate complete resolution of the bacteria. Using μMT mice and 
serum transfer studies we further assessed the relative roles of immunity in the URT and 
LRT of Mp infected mice. Transfer of WT immune serum, containing Mp-specific IgG, 
controlled Mp pulmonary infection in lungs of μMT mice but did not lead to a reduction of Mp 
loads in the nose. Together, these observations demonstrate the importance of local 
immunity. Yet, why IgA cannot clear bacterial carriage in the URT is unknown [40]. Mp is not 
known to possess IgA protease activity [41]. Also, increasing local specific IgA responses by 
immunization did not lead to a corresponding reduction of mycoplasma bacterial loads in the 
nose [39], which suggests that enhancing IgA responses alone does not control carriage in 
the URT. 
 Our observation that Mp infections are more severe – and chronic – in µMT mice may 
resemble the findings in patients that suffer from B cell deficiencies [42], such as common 
variable immunodeficiency, X-linked agammaglobulinemia or hypogammaglobulinemia, who 
have been reported to be at increased risk for Mp pulmonary disease and/or extrapulmonary 
manifestations, e.g., arthritis [21-25]. It can be speculated that if these patients experience 
Mp infections, they may benefit from intravenous immunoglobulin (IVIg) treatment, as our 
data demonstrate that administration of serum containing Mp-specific IgG protected µMT 
mice from pulmonary Mp infections. In fact, high amounts of Mp-specific IgG can be detected 
in commercial human IVIg preparations [43]. 
 While the Mp mouse model provides a useful tool to investigate the immunological 
processes involved in controlling infection of the lungs and carriage in the nose, the use of 
the human pathogen Mp instead of M. pulmonis [44] can be a limitation of our study 
considering the genomic differences between these pathogens [45]. 
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 Together, we show for the first time that, like in humans, Mp is carried in the URT of 
mice after symptomatic infection. In addition, we demonstrate that B cells and Mp-specific 
antibodies are crucial for Mp clearance in the lungs of mice, but are limited in clearing Mp 
from the URT. These novel aspects of Mp–host interactions will aid the understanding of Mp 
pathogenesis and promote the development of Mp-targeting vaccines to prevent the 
progress of Mp pulmonary disease in individuals that carry Mp. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 16 
Funding 
P.M.M.S. was supported by grants of the Swiss National Science Foundation 
(PBZHP3_147290), the Promedica Foundation (Chur, Switzerland), and a Fellowship Award 
of the European Society for Paediatric Infectious Diseases (ESPID). R.C.A.d.G. was 
supported by the Sophia Scientific Research Foundation (SSWO 2014–150/WO). A.M.C.v.R. 
was supported by grants of the NuthsOhra Foundation and the Thrasher Foundation. The 
funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript. 
 
Conflict of interest 
None. 
 
Acknowledgments 
We thank the Erasmus Medical Center experimental animal facility for their care for our mice 
and assistance at experiments, Dicky J. Lindenbergh-Kortleve and Lisette A. van Berkel 
(Laboratory of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus MC–Sophia 
Children’s Hospital) for technical support and advice, and Derek Reijerkerk and Carla Baan 
(Department of Immunology, Erasmus MC) for technical support with the ELISpot assay. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 17 
References 
1. Meyer Sauteur PM, Unger WWJ, Nadal D, Berger C, Vink C, van Rossum AMC. 
Infection with and carriage of Mycoplasma pneumoniae in children. Front Microbiol 
2016; 7:329. 
2. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring 
hospitalization among U.S. children. N Engl J Med 2015; 372:835-45. 
3. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in 
the upper respiratory tract of symptomatic and asymptomatic children: an 
observational study. PLoS Med 2013; 10:e1001444. 
4. Foy HM. Infections caused by Mycoplasma pneumoniae and possible carrier state in 
different populations of patients. Clin Infect Dis 1993; 17 Suppl 1:S37-46. 
5. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, Bartelds AI, Heijnen ML, Dankert J. 
Results of molecular detection of Mycoplasma pneumoniae among patients with 
acute respiratory infection and in their household contacts reveals children as human 
reservoirs. J Infect Dis 2001; 183:675-8. 
6. Nilsson AC, Bjorkman P, Persson K. Polymerase chain reaction is superior to 
serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a 
high rate of persistent infection. BMC Microbiol 2008; 8:93. 
7. Wood PR, Hill VL, Burks ML, et al. Mycoplasma pneumoniae in children with acute 
and refractory asthma. Ann Allergy Asthma Immunol 2013; 110:328-34 e1. 
8. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the 
key to pneumococcal disease. Lancet Infect Dis 2004; 4:144-54. 
9. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of 
Staphylococcus aureus bacteremia. N Engl J Med 2001; 344:11-6. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 18 
10. Gray BM, Converse GM, 3rd, Dillon HC, Jr. Epidemiologic studies of Streptococcus 
pneumoniae in infants: acquisition, carriage, and infection during the first 24 months 
of life. J Infect Dis 1980; 142:923-33. 
11. Casadevall A, Pirofski LA. Host-pathogen interactions: basic concepts of microbial 
commensalism, colonization, infection, and disease. Infect Immun 2000; 68:6511-8. 
12. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol 2015;  
13. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human 
pathogen. Clin Microbiol Rev 2004; 17:697-728. 
14. Meyer Sauteur PM, Jacobs BC, Spuesens EB, et al. Antibody responses to 
Mycoplasma pneumoniae: role in pathogenesis and diagnosis of encephalitis? PLoS 
Pathog 2014; 10:e1003983. 
15. Granstrom M, Holme T, Sjogren AM, Ortqvist A, Kalin M. The role of IgA 
determination by ELISA in the early serodiagnosis of Mycoplasma pneumoniae 
infection, in relation to IgG and mu-capture IgM methods. J Med Microbiol 1994; 
40:288-92. 
16. Berglof A, Sandstedt K, Feinstein R, Bolske G, Smith CI. B cell-deficient muMT mice 
as an experimental model for mycoplasma infections in X-linked 
agammaglobulinemia. Eur J Immunol 1997; 27:2118-21. 
17. Sandstedt K, Berglof A, Feinstein R, Bolske G, Evengard B, Smith CI. Differential 
susceptibility to Mycoplasma pulmonis intranasal infection in X-linked 
immunodeficient (xid), severe combined immunodeficient (scid), and 
immunocompetent mice. Clin Exp Immunol 1997; 108:490-6. 
18. Evengard B, Sandstedt K, Bolske G, Feinstein R, Riesenfelt-Orn I, Smith CI. 
Intranasal inoculation of Mycoplasma pulmonis in mice with severe combined 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 19 
immunodeficiency (SCID) causes a wasting disease with grave arthritis. Clin Exp 
Immunol 1994; 98:388-94. 
19. Hayatsu E. Acquired immunity to Mycoplasma pneumoniae. Pneumonia in hamsters. 
Microbiol Immunol 1978; 22:181-95. 
20. Hayatsu E, Kawakubo Y, Yayoshi M, Araake M, Yoshioka M, Nishiyama Y. Role of 
humoral antibodies in resistance to Mycoplasma pneumoniae pneumonia in 
hamsters. Microbiol Immunol 1980; 24:585-93. 
21. Taylor-Robinson D, Gumpel JM, Hill A, Swannell AJ. Isolation of Mycoplasma 
pneumoniae from the synovial fluid of a hypogammaglobulinaemic patient in a survey 
of patients with inflammatory polyarthritis. Ann Rheum Dis 1978; 37:180-2. 
22. Taylor-Robinson D, Webster AD, Furr PM, Asherson GL. Prolonged persistence of 
Mycoplasma pneumoniae in a patient with hypogammaglobulinaemia. J Infect 1980; 
2:171-5. 
23. Roifman CM, Rao CP, Lederman HM, Lavi S, Quinn P, Gelfand EW. Increased 
susceptibility to Mycoplasma infection in patients with hypogammaglobulinemia. Am J 
Med 1986; 80:590-4. 
24. Furr PM, Taylor-Robinson D, Webster AD. Mycoplasmas and ureaplasmas in patients 
with hypogammaglobulinaemia and their role in arthritis: microbiological observations 
over twenty years. Ann Rheum Dis 1994; 53:183-7. 
25. Franz A, Webster AD, Furr PM, Taylor-Robinson D. Mycoplasmal arthritis in patients 
with primary immunoglobulin deficiency: clinical features and outcome in 18 patients. 
Br J Rheumatol 1997; 36:661-8. 
26. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted 
disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991; 
350:423-6. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 20 
27. Simecka JW, Patel P, Davis JK, Ross SE, Otwell P, Cassell GH. Specific and 
nonspecific antibody responses in different segments of the respiratory tract in rats 
infected with Mycoplasma pulmonis. Infect Immun 1991; 59:3715-21. 
28. Spuesens EB, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AM, Vink C. 
Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae 
by pyrosequencing. J Microbiol Methods 2010; 82:214-22. 
29. van den Brand JM, Stittelaar KJ, van Amerongen G, et al. Severity of pneumonia due 
to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal 
H1N1 virus and highly pathogenic avian influenza H5N1 virus. J Infect Dis 2010; 
201:993-9. 
30. Hardy RD, Jafri HS, Olsen K, et al. Elevated cytokine and chemokine levels and 
prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae 
pneumonia model: a microbiologic, histologic, immunologic, and respiratory 
plethysmographic profile. Infect Immun 2001; 69:3869-76. 
31. Fonseca-Aten M, Rios AM, Mejias A, et al. Mycoplasma pneumoniae induces host-
dependent pulmonary inflammation and airway obstruction in mice. Am J Respir Cell 
Mol Biol 2005; 32:201-10. 
32. Kannan TR, Coalson JJ, Cagle M, Musatovova O, Hardy RD, Baseman JB. Synthesis 
and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a 
murine model. J Infect Dis 2011; 204:1596-604. 
33. Lyons AB, Parish CR. Determination of lymphocyte division by flow cytometry. J 
Immunol Methods 1994; 171:131-7. 
34. Dallo SF, Baseman JB. Intracellular DNA replication and long-term survival of 
pathogenic mycoplasmas. Microb Pathog 2000; 29:301-9. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 21 
35. Meseguer MA, Alvarez A, Rejas MT, Sanchez C, Perez-Diaz JC, Baquero F. 
Mycoplasma pneumoniae: a reduced-genome intracellular bacterial pathogen. Infect 
Genet Evol 2003; 3:47-55. 
36. Sealy R, Surman S, Hurwitz JL, Coleclough C. Antibody response to influenza 
infection of mice: different patterns for glycoprotein and nucleocapsid antigens. 
Immunology 2003; 108:431-9. 
37. Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the 
respiratory tract mucosa. Jpn J Infect Dis 2004; 57:236-47. 
38. Waffarn EE, Baumgarth N. Protective B cell responses to flu--no fluke! J Immunol 
2011; 186:3823-9. 
39. Hodge LM, Simecka JW. Role of upper and lower respiratory tract immunity in 
resistance to Mycoplasma respiratory disease. J Infect Dis 2002; 186:290-4. 
40. Wolfe DN, Kirimanjeswara GS, Goebel EM, Harvill ET. Comparative role of 
immunoglobulin A in protective immunity against the Bordetellae. Infect Immun 2007; 
75:4416-22. 
41. Robertson JA, Stemler ME, Stemke GW. Immunoglobulin A protease activity of 
Ureaplasma urealyticum. J Clin Microbiol 1984; 19:255-8. 
42. Fried AJ, Bonilla FA. Pathogenesis, diagnosis, and management of primary antibody 
deficiencies and infections. Clin Microbiol Rev 2009; 22:396-414. 
43. Meyer Sauteur PM, Huizinga R, Tio-Gillen AP, et al. Mycoplasma pneumoniae 
triggering the Guillain-Barre syndrome: A case-control study. Ann Neurol 2016; 
80:566-80. 
44. Lindsey JR, Baker HJ, Overcash RG, Cassell GH, Hunt CE. Murine chronic 
respiratory disease. Significance as a research complication and experimental 
production with Mycoplasma pulmonis. Am J Pathol 1971; 64:675-708. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 22 
45. Chambaud I, Heilig R, Ferris S, et al. The complete genome sequence of the murine 
respiratory pathogen Mycoplasma pulmonis. Nucleic Acids Res 2001; 29:2145-53. 
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 23 
Figures 
Figure 1. Mp persists in the nose after pulmonary infection of C57BL/6 WT mice. 
C57BL/6 WT mice were infected intranasally with 1×109 CFU Mp M129 (black circles) or 
mock-infected with SP4 medium (white circles). (A) Body weight changes were monitored at 
indicated time points p.i. and expressed as percentage of body weight at day 0; the mean ± 
standard deviation (SD) of each group (n=6–16 mice/time point) is shown. *p<0.05, 
***p<0.001 (Welch’s t-test with Holm-Bonferroni method correction). (B–C) Bacterial loads as 
CFU/ml in BALF and nasal lavage fluid; values are expressed as median with interquartile 
range (IQR). (D–E) Immunofluorescent images of lung and nasal sections of C57BL/6 WT 
mice (n=3 mice/time point) at indicated time points after intrana al inoculation with 1×109 
CFU CFSE-labeled Mp M129 (image: 200× magnification; inset: 1000× magnification). 
 
Figure 2. Mp pneumonia is characterized by alveolar and bronchiolar immune cell 
infiltrates at day three p.i. C57BL/6 WT mice were Mp-infected (black bars) or mock-
infected (white bars). (A) Histopathology score for mice at indicated time points p.i.; bars 
represent the median ± IQR of each group (n=6 mice/time point). *p<0.05 (Kruskal-Wallis 
test with post hoc Dunn’s multiple comparisons test). (B) Representative lung paraffin 
sections from Mp-inf cted and control mice on day 3 p.i., stained with hematoxylin and eosin 
(H&E) (image: 50× magnification; inset: 200× magnification). 
 
Figure 3. Mp-specific serum antibodies have neutralizing capacities. (A–B) Mp-specific 
antibody titers in serum of Mp-infected (black circles) and control treated (white circles) 
C57BL/6 WT mice (n=6–16 mice/group/time point): (A) Mp-specific IgM, IgG, and IgA at 
indicated time points; (B) Mp-specific IgG subclasses IgG1 and IgG2a at day 42 p.i. Dots 
represent individual mice and the horizontal line in each graph the median. (C) Mp was 
incubated with sera from infected (dark gray box) or uninfected (light gray box) C57BL/6 mice 
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or with medium (white box), and subsequently co-cultured with RAW cells for 20 min. After 
washing, phagocytosis and killing of Mp was determined based on the number of CFU/105 
RAW cells recovered. The box represents the lower and upper quartiles and the median is 
shown as a line across the box. Whiskers extend to the maximum or minimum values within 
1.5 times the IQR above and below the 3rd and 1st quartile, respectively. *p<0.05, **p<0.01 
(A: Kruskal-Wallis test with post hoc Dunn’s multiple comparisons test; B: Mann-Whitney U 
test). 
 
Figure 4. Differential B cell activation in upper versus lower respiratory tract. (A) 
Analysis of Mp-specific IgG and IgA antibody titers in BALF and nasal lavage fluid at 42 days 
p.i. (IgG) and 28 days p.i. (IgA) of Mp- and mock-infected C57BL/6 mice (n=4–6 
mice/group/time point). (B) Analysis of Mp-specific and total IgA antibody-secreting cells 
(ASCs) in MLNs, CLNs, and nasal passages at 7 days p.i. of Mp-infected C57BL/6 mice 
(n=3–6 mice). (C) Number of CD19+MHCII+ B cells in MLNs, CLNs, and inguinal PLNs. (D–
E) CD86+ B cell numbers (D) and mean fluorescence intensity (MFI) (E) as ratio to medium 
controls in MLNs and CLNs. Bars and horizontal lines indicate the median and dots individual 
mice. *p<0.05, **p<0.01 (A: Mann-Whitney U test; B–E: Kruskal-Wallis test with post hoc 
Dunn’s multiple comparisons test). 
 
Figure 5. µMT mice show limited pulmonary clearance of Mp and higher nasal carriage 
rates. C57BL/6 WT mice (black circles) and μMT mice (gray squares) were infected 
intranasally with Mp. Control mice (white circles) received SP4 medium alone. (A) Body 
weight changes were monitored at indicated time points p.i. and expressed as percentage of 
body weight at day 0; the mean ± SD of each group is shown (n=6–13 mice/time point). (B–
C) Bacterial loads as CFU/ml in BALF and nasal lavage fluid; values are expressed as 
median with IQR. (D) Histopathology score for mice at indicated time points p.i.; the mean ± 
SD of each group (n=6–7 mice/time point) is shown. (E) Absolute number of leukocytes in 
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lungs at different days p.i. (F) Numbers of lung granulocytes (Ly6G+CD11bhiCD11c-), 
monocytes (CD11bhiLy6G-CD11c-), CD4+ T cells (CD3+CD4+), and CD8+ T cells (CD3+CD8+). 
(G) IL-6, MCP-1, MIP1β, and TNF-α in nasal lavage fluids of Mp-infected WT and μMT mice 
were determined by multiplex fluorescent-bead-based immunoassay. Median levels with IQR 
are shown. *p<0.05, **p<0.01 (A: Welch’s t-test with Holm-Bonferroni method correction; B–
C: Mann-Whitney U test with Holm-Bonferroni method correction; D–F: Kruskal-Wallis test 
with post hoc Dunn’s multiple comparisons test; A–C: μMT vs. infected WT mice). 
 
Figure 6. Adoptive transfer of WT serum allows μMT mice to control Mp infection in 
the lungs. (A) Experimental setup of the serum transfer experiment (n=6 mice/group). (B–C) 
Bacterial loads as CFU/ml in BALF and nasal lavage fluid of WT and μMT mice. (D) Mp-
specific IgG levels (AU/ml) in BALF of WT and μMT mice. (E) Correlation between Mp-
specific IgG and bacterial load in BALF of μMT recipient mice that were passively immunized 
or control injected. The p value is indicated in the graphs (B–D: Mann-Whitney U test; E: 
Pearson product moment correlation coefficient). 
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Figure 1. 
 
 
  
Downloaded from https://academic.oup.com/jid/article-abstract/doi/10.1093/infdis/jix559/4584507
by Edinburgh University user
on 13 November 2017
Ac
ce
pte
d M
an
us
cri
pt
 
  Page 27 
Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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